CanVIG-UK Resources
UKCGG/CStAG Statements
UKCGG/CStAG statement on reporting practice for variants in ATM
Version: v2.2
Date: 08/10/2025
Statement to propose strategies for analysis and reporting of ATM variants in different contexts.
Where analysis is recommended, variants should be interpreted and classified using ATM VCEP guidelines and CanVIG gene-specific recommendations.
Previous Versions:
UKCGG/CStAG statement on reporting practice for variants in "moderate risk" breast cancer susceptibility genes
Version: v2.0
Date: 28/06/2026
Statement to propose strategies for analysis and reporting of variants in "moderate risk" breast cancer susceptibility genes. **Please note this document supersedes the previous reporting practice statement for variants in CHEK2.**
​​
Previous Versions:
UKCGG/CStAG statement on extension of testing undertaken under R444.1 to include PALB2
Version: v1.0
Date: 12/02/2025
Statement to recommend that patients tested under R444.1 receive germline genetic testing of BRCA1, BRCA2 AND PALB2.
​​
Previous Versions:
Version: v1.2
Version 1.1
UKCGG/CanVIG framework for germline follow-up of variants picked up through tumour testing
Version: v1.0
Date: 11/06/2025
Statement to document the recommendations of the UKCCG/CStAG for germline follow-up of variants identified through tumour testing or ctDNA sampling.
Previous Versions:
Version: v1.2
Version 1.1
Interpretation and follow-up of CNVs in cancer susceptibility genes detected via tumour testing
Version: v1.0
Date: 13/01/2026
Statement to document the recommendations of the UKCCG/CStAG for germline testing of single/multi-exon Copy Number Variants (CNVs) detected via tumour testing.
Previous Versions:
Version: v1.2
Version 1.1
Exception Variant reporting list
Version: v2.0
Date: 09/10/2025
There are certain genes in which variability in penetrance associated with different variants is such that not all variants will be reported by NHS laboratories/UK practice.
It is not feasible to maintain a formal whitelist of exception variants, but laboratory teams are encouraged to communicate rationale for reporting of non-standard variants via CanVar-UK.
Previous Versions:
UKCGG/CStAG Statement on the management of carriers of Germline Pathogenic TP53 Variants associated with atypical and/or reduced penetrance
Version: v1.0
Date: 02/11/2026
Recommendations to support consistent interpretation, reporting and clinical management, recognising the challenges of applying recommendations developed for carriers of variants associated with standard penetrance to those carrying variants associated with reduced or atypical penetrance. The latter may be a more appropriate description in many cases.
Previous Versions:
UKCGG / CanVIG-UK Position Statement: Constitutional MBD4 testing and reporting
Version: v1.0
Date: 02/11/2026
Recommendations to support consistent reporting and clinical management of heterozygous and biallelic pathogenic variants, including considerations around reproductive partner testing.
Previous Versions:
Other CanVIG-UK variant resources
CanVIG-UK Summary Variant List (live sync)
A summary list of variants previously classified by the CanVIG-UK group or currently in progress. For full consensus classifications, please see CanVar-UK or ClinVar.
Please note; variant review by CanVIG-UK is limited to variants dictated by members as pertinent to the development of cancer variant interpretation guidance. At this time, we do not have the capacity to formally review variants outside this remit.
External Resources
